Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor.

Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky AJ.

J Pharmacol Exp Ther. 2018 Jun 11. pii: jpet.118.248120. doi: 10.1124/jpet.118.248120. [Epub ahead of print]

2.

Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.

Du G, Lewis MM, Sica C, He L, Connor JR, Kong L, Mailman RB, Huang X.

Mov Disord. 2018 May 14. doi: 10.1002/mds.27318. [Epub ahead of print]

PMID:
29756399
3.

Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.

Lewis MM, Du G, Baccon J, Snyder AM, Murie B, Cooper F, Stetter C, Kong L, Sica C, Mailman RB, Connor JR, Huang X.

Mov Disord. 2018 May 14. doi: 10.1002/mds.27381. [Epub ahead of print]

PMID:
29756231
4.

Strategic neuronal encoding in medial prefrontal cortex of spatial working memory in the T-maze.

Yang Y, Mailman RB.

Behav Brain Res. 2018 May 2;343:50-60. doi: 10.1016/j.bbr.2018.01.020. Epub 2018 Jan 31.

PMID:
29378292
5.

Circulating Cholesterol Levels May Link to the Factors Influencing Parkinson's Risk.

Zhang L, Wang X, Wang M, Sterling NW, Du G, Lewis MM, Yao T, Mailman RB, Li R, Huang X.

Front Neurol. 2017 Sep 27;8:501. doi: 10.3389/fneur.2017.00501. eCollection 2017.

6.

Welding-related brain and functional changes in welders with chronic and low-level exposure.

Lee EY, Flynn MR, Lewis MM, Mailman RB, Huang X.

Neurotoxicology. 2018 Jan;64:50-59. doi: 10.1016/j.neuro.2017.06.011. Epub 2017 Jun 23.

PMID:
28648949
7.

Lateralized Basal Ganglia Vulnerability to Pesticide Exposure in Asymptomatic Agricultural Workers.

Lewis MM, Sterling NW, Du G, Lee EY, Shyu G, Goldenberg M, Allen T, Stetter C, Kong L, Amy Snipes S, Jones BC, Chen H, Mailman RB, Huang X.

Toxicol Sci. 2017 Sep 1;159(1):170-178. doi: 10.1093/toxsci/kfx126.

PMID:
28633499
8.

Projection of the prevalence of Parkinson's disease in the coming decades: Revisited.

Rossi A, Berger K, Chen H, Leslie D, Mailman RB, Huang X.

Mov Disord. 2018 Jan;33(1):156-159. doi: 10.1002/mds.27063. Epub 2017 Jun 7.

PMID:
28590580
9.

Statins may facilitate Parkinson's disease: Insight gained from a large, national claims database.

Liu G, Sterling NW, Kong L, Lewis MM, Mailman RB, Chen H, Leslie D, Huang X.

Mov Disord. 2017 Jun;32(6):913-917. doi: 10.1002/mds.27006. Epub 2017 Apr 3.

10.

Association of neurobehavioral performance with R2* in the caudate nucleus of asymptomatic welders.

Lee EY, Eslinger PJ, Flynn MR, Wagner D, Du G, Lewis MM, Kong L, Mailman RB, Huang X.

Neurotoxicology. 2017 Jan;58:66-74. doi: 10.1016/j.neuro.2016.11.007. Epub 2016 Nov 18.

11.

Longitudinal T1 relaxation rate (R1) captures changes in short-term Mn exposure in welders.

Lewis MM, Flynn MR, Lee EY, Van Buren S, Van Buren E, Du G, Fry RC, Herring AH, Kong L, Mailman RB, Huang X.

Neurotoxicology. 2016 Dec;57:39-44. doi: 10.1016/j.neuro.2016.08.012. Epub 2016 Aug 24.

12.

Editor's Highlight: Lower Fractional Anisotropy in the Globus Pallidus of Asymptomatic Welders, a Marker for Long-Term Welding Exposure.

Lee EY, Flynn MR, Du G, Lewis MM, Herring AH, Van Buren E, Van Buren S, Kong L, Mailman RB, Huang X.

Toxicol Sci. 2016 Sep;153(1):165-73. doi: 10.1093/toxsci/kfw116. Epub 2016 Jul 27.

13.

Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Arnsten AF, Girgis RR, Gray DL, Mailman RB.

Biol Psychiatry. 2017 Jan 1;81(1):67-77. doi: 10.1016/j.biopsych.2015.12.028. Epub 2016 Jan 18. Review.

14.

Increased R2* in the Caudate Nucleus of Asymptomatic Welders.

Lee EY, Flynn MR, Du G, Li Y, Lewis MM, Herring AH, Van Buren E, Van Buren S, Kong L, Fry RC, Snyder AM, Connor JR, Yang QX, Mailman RB, Huang X.

Toxicol Sci. 2016 Apr;150(2):369-77. doi: 10.1093/toxsci/kfw003. Epub 2016 Jan 14.

15.

The V81M variant of tyrosine hydroxylase is associated with more severe freezing of gait in Parkinson's disease.

Tekin I, Carkaci-Salli N, Lewis MM, Mailman RB, Huang X, Vrana KE.

Parkinsonism Relat Disord. 2016 Feb;23:86-90. doi: 10.1016/j.parkreldis.2015.12.015. Epub 2015 Dec 23.

16.

The pattern of gray matter atrophy in Parkinson's disease differs in cortical and subcortical regions.

Lewis MM, Du G, Lee EY, Nasralah Z, Sterling NW, Zhang L, Wagner D, Kong L, Tröster AI, Styner M, Eslinger PJ, Mailman RB, Huang X.

J Neurol. 2016 Jan;263(1):68-75. doi: 10.1007/s00415-015-7929-7.

17.

Quantitative susceptibility mapping of the midbrain in Parkinson's disease.

Du G, Liu T, Lewis MM, Kong L, Wang Y, Connor J, Mailman RB, Huang X.

Mov Disord. 2016 Mar;31(3):317-24. doi: 10.1002/mds.26417. Epub 2015 Sep 12.

18.

T1 Relaxation Rate (R1) Indicates Nonlinear Mn Accumulation in Brain Tissue of Welders With Low-Level Exposure.

Lee EY, Flynn MR, Du G, Lewis MM, Fry R, Herring AH, Van Buren E, Van Buren S, Smeester L, Kong L, Yang Q, Mailman RB, Huang X.

Toxicol Sci. 2015 Aug;146(2):281-9. doi: 10.1093/toxsci/kfv088. Epub 2015 May 7.

19.

Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study.

Huang X, Alonso A, Guo X, Umbach DM, Lichtenstein ML, Ballantyne CM, Mailman RB, Mosley TH, Chen H.

Mov Disord. 2015 Apr;30(4):552-9. doi: 10.1002/mds.26152. Epub 2015 Jan 14.

20.

Transcriptional repression by the BRG1-SWI/SNF complex affects the pluripotency of human embryonic stem cells.

Zhang X, Li B, Li W, Ma L, Zheng D, Li L, Yang W, Chu M, Chen W, Mailman RB, Zhu J, Fan G, Archer TK, Wang Y.

Stem Cell Reports. 2014 Sep 9;3(3):460-74. doi: 10.1016/j.stemcr.2014.07.004. Epub 2014 Aug 14.

21.

Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder.

Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, Harvey PD, Girgis RR, Hazlett EA, Mailman RB, Abi-Dargham A, Lieberman JA, Siever LJ.

Neuropsychopharmacology. 2015 Jan;40(2):446-53. doi: 10.1038/npp.2014.192. Epub 2014 Jul 30.

22.

A novel role of CDX1 in embryonic epicardial development.

Chu M, Wang L, Wang H, Shen T, Yang Y, Sun Y, Tang N, Ni T, Zhu J, Mailman RB, Wang Y.

PLoS One. 2014 Jul 28;9(7):e103271. doi: 10.1371/journal.pone.0103271. eCollection 2014.

23.

Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?

Lee SM, Yang Y, Mailman RB.

J Pharmacol Exp Ther. 2014 Oct;351(1):9-17. doi: 10.1124/jpet.114.214411. Epub 2014 Jul 22. Review.

24.

Response.

Jones BC, Huang X, Mailman RB, Lu L, Williams RW.

J Biochem Mol Toxicol. 2014 Jul;28(7):291. doi: 10.1002/jbt.21591_2. No abstract available.

PMID:
25044316
25.

SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C.

Lee SM, Kant A, Blake D, Murthy V, Boyd K, Wyrick SJ, Mailman RB.

Neuropharmacology. 2014 Nov;86:145-54. doi: 10.1016/j.neuropharm.2014.05.042. Epub 2014 Jun 12.

26.

The perplexing paradox of paraquat: the case for host-based susceptibility and postulated neurodegenerative effects.

Jones BC, Huang X, Mailman RB, Lu L, Williams RW.

J Biochem Mol Toxicol. 2014 May;28(5):191-7. doi: 10.1002/jbt.21552. Epub 2014 Mar 5. Review.

27.

Microstructural changes in the substantia nigra of asymptomatic agricultural workers.

Du G, Lewis MM, Sterling NW, Kong L, Chen H, Mailman RB, Huang X.

Neurotoxicol Teratol. 2014 Jan-Feb;41:60-4. doi: 10.1016/j.ntt.2013.12.001. Epub 2013 Dec 12.

28.

Higher iron in the red nucleus marks Parkinson's dyskinesia.

Lewis MM, Du G, Kidacki M, Patel N, Shaffer ML, Mailman RB, Huang X.

Neurobiol Aging. 2013 May;34(5):1497-503. doi: 10.1016/j.neurobiolaging.2012.10.025. Epub 2012 Nov 21.

29.

Dopamine receptor signaling and current and future antipsychotic drugs.

Boyd KN, Mailman RB.

Handb Exp Pharmacol. 2012;(212):53-86. doi: 10.1007/978-3-642-25761-2_3. Review.

30.

Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.

Du G, Lewis MM, Shaffer ML, Chen H, Yang QX, Mailman RB, Huang X.

PLoS One. 2012;7(4):e35397. doi: 10.1371/journal.pone.0035397. Epub 2012 Apr 17.

31.

Receptor conformations involved in dopamine D(2L) receptor functional selectivity induced by selected transmembrane-5 serine mutations.

Fowler JC, Bhattacharya S, Urban JD, Vaidehi N, Mailman RB.

Mol Pharmacol. 2012 Jun;81(6):820-31. doi: 10.1124/mol.111.075457. Epub 2012 Mar 13.

32.

Apolipoprotein E genotypes and the risk of Parkinson disease.

Gao J, Huang X, Park Y, Liu R, Hollenbeck A, Schatzkin A, Mailman RB, Chen H.

Neurobiol Aging. 2011 Nov;32(11):2106.e1-6. doi: 10.1016/j.neurobiolaging.2011.05.016. Epub 2011 Jul 8.

33.

Differential involvement of striato- and cerebello-thalamo-cortical pathways in tremor- and akinetic/rigid-predominant Parkinson's disease.

Lewis MM, Du G, Sen S, Kawaguchi A, Truong Y, Lee S, Mailman RB, Huang X.

Neuroscience. 2011 Mar 17;177:230-9. doi: 10.1016/j.neuroscience.2010.12.060. Epub 2011 Jan 4.

34.

Smoking duration, intensity, and risk of Parkinson disease.

Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, Umbach DM, Xu Q, Hollenbeck A, Schatzkin A, Blair A.

Neurology. 2010 Mar 16;74(11):878-84. doi: 10.1212/WNL.0b013e3181d55f38. Epub 2010 Mar 10.

35.

Ligand functional selectivity advances our understanding of drug mechanisms and drug discovery.

Mailman RB, Murthy V.

Neuropsychopharmacology. 2010 Jan;35(1):345-6. doi: 10.1038/npp.2009.117. No abstract available.

36.
37.

Asymmetrical lateral ventricular enlargement in Parkinson's disease.

Lewis MM, Smith AB, Styner M, Gu H, Poole R, Zhu H, Li Y, Barbero X, Gouttard S, McKeown MJ, Mailman RB, Huang X.

Eur J Neurol. 2009 Apr;16(4):475-81. doi: 10.1111/j.1468-1331.2008.02430.x.

38.

Rapid, semi-automated, and inexpensive radioimmunoassay of cAMP: application in GPCR-mediated adenylate cyclase assays.

Brown JT, Kant A, Mailman RB.

J Neurosci Methods. 2009 Mar 15;177(2):261-6. doi: 10.1016/j.jneumeth.2008.10.016. Epub 2008 Oct 21.

39.

Dopamine receptor pharmacology.

Mailman RB, Huang X.

Handb Clin Neurol. 2007;83:77-105. doi: 10.1016/S0072-9752(07)83004-1. No abstract available.

PMID:
18808911
40.

Low LDL cholesterol and increased risk of Parkinson's disease: prospective results from Honolulu-Asia Aging Study.

Huang X, Abbott RD, Petrovitch H, Mailman RB, Ross GW.

Mov Disord. 2008 May 15;23(7):1013-1018. doi: 10.1002/mds.22013.

PMID:
18381649
41.

GPCR functional selectivity has therapeutic impact.

Mailman RB.

Trends Pharmacol Sci. 2007 Aug;28(8):390-6. Epub 2007 Jul 13. Review.

42.

A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia.

Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS.

Schizophr Res. 2007 Aug;94(1-3):332-41. Epub 2007 Jun 27.

PMID:
17596915
43.

Task specific influences of Parkinson's disease on the striato-thalamo-cortical and cerebello-thalamo-cortical motor circuitries.

Lewis MM, Slagle CG, Smith AB, Truong Y, Bai P, McKeown MJ, Mailman RB, Belger A, Huang X.

Neuroscience. 2007 Jun 15;147(1):224-35. Epub 2007 May 17.

44.

A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.

George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB.

Schizophr Res. 2007 Jul;93(1-3):42-50. Epub 2007 Apr 30.

PMID:
17467956
45.

Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease.

Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, Xiang D, Murrow RW, Wang YZ, Poole C.

Mov Disord. 2007 Feb 15;22(3):377-81.

46.

Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors.

Ryman-Rasmussen JP, Griffith A, Oloff S, Vaidehi N, Brown JT, Goddard WA 3rd, Mailman RB.

Neuropharmacology. 2007 Feb;52(2):562-75. Epub 2006 Oct 24.

47.

Low affinity binding of the classical D1 antagonist SCH23390 in rodent brain: potential interaction with A2A and D2-like receptors.

Leonard SK, Ferry-Leeper P, Mailman RB.

Brain Res. 2006 Oct 30;1117(1):25-37. Epub 2006 Sep 7.

48.

Functional selectivity and classical concepts of quantitative pharmacology.

Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB.

J Pharmacol Exp Ther. 2007 Jan;320(1):1-13. Epub 2006 Jun 27. Review.

49.

D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease.

Lewis MM, Huang X, Nichols DE, Mailman RB.

CNS Neurol Disord Drug Targets. 2006 Jun;5(3):345-53. Review.

PMID:
16787233
50.

Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.

Urban JD, Vargas GA, von Zastrow M, Mailman RB.

Neuropsychopharmacology. 2007 Jan;32(1):67-77. Epub 2006 Mar 22.

Supplemental Content

Loading ...
Support Center